Beijing Creative Medicine

Beijing Creative Medicine is a Chinese biotechnology company focused on the discovery and development of innovative small molecule drugs, primarily in the fields of oncology and ophthalmology. The company is best known for its lead product, Vorolanib (CM082), a multi-target tyrosine kinase inhibitor that selectively targets VEGFR, PDGFR, and c-Kit. Vorolanib was developed to provide potent anti-angiogenic activity while reducing the systemic toxicities typically associated with this class of drugs. In 2023, the drug received marketing approval in China for the treatment of renal cell carcinoma in combination with everolimus. Beijing Creative Medicine operates as a wholly-owned subsidiary of Betta Pharmaceuticals, which acquired the company to consolidate the development of its promising pipeline. The company continues to advance clinical trials for Vorolanib in other indications, including wet age-related macular degeneration.